Equity Overview
Price & Market Data
Price: $0.032
Daily Change: +$0.0067 / 20.94%
Daily Range: $0.025 - $0.0322
Market Cap: $2,414,796
Daily Volume: 527,947
Performance Metrics
1 Week: 45.45%
1 Month: 28.51%
3 Months: 59.20%
6 Months: 32.78%
1 Year: -23.81%
YTD: 45.45%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.